leflunomide has been researched along with Autoimmune Disease in 33 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis." | 8.81 | Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. ( Harisdangkul, V; Sanders, S, 2002) |
| "Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA)." | 8.80 | Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. ( Herrmann, ML; Kirschbaum, BJ; Schleyerbach, R, 2000) |
| "To investigate the protective efficacy of leflunomide on the Lewis rats with experimental autoimmune uveitis (EAU)." | 7.81 | [Effects of leflunomide on experimental autoimmune uveitis in Lewis rats]. ( Fang, C; He, Y; Huang, C; Li, J; Lin, Z; Zhan, S; Zhou, D, 2015) |
| "To investigate the efficacy of leflunomide in experimental autoimmune uveitis (EAU) in rats." | 7.79 | Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. ( Fang, CB; He, Y; Huang, C; Li, J; Lin, Z; Zhan, SX; Zhou, DX, 2013) |
| "To evaluate efficacy and adverse effects of leflunomide for the treatment of naturally occurring immune-mediated polyarthritis (IMPA) in dogs." | 7.76 | Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). ( Baker, TA; Colopy, SA; Muir, P, 2010) |
| "Leflunomide (LEF) is a novel immunomodulator which has been reported to be efficacious in experimental models of systemic autoimmune diseases and in treating rheumatoid arthritis in man." | 7.69 | Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. ( Lang, LS; Robertson, SM, 1994) |
| "Leflunomide has been successfully used for treating rheumatoid arthritis and psoriatic arthritis for many years." | 6.52 | Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. ( Brooks, JB; Fragoso, YD, 2015) |
| "Leflunomide is a classic disease-modifying anti-rheumatic drug that is widely used to treat autoimmune diseases." | 5.41 | Leflunomide: Traditional immunosuppressant with concurrent antiviral effects. ( Chen, Y; He, C; Li, M; Liu, S; Wang, L; Wu, D; Yang, Y; Zeng, X; Zhang, F; Zheng, K, 2023) |
| "Brequinar sodium (BQR) was originally developed as an antitumor drug and subsequently as an immunosuppressant for controlling transplant rejection." | 5.30 | Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action. ( Blinder, L; Chong, AS; Gong, H; Shen, J; Williams, JW; Xu, X, 1997) |
| "Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function." | 5.29 | Leflunomide prevents the development of experimentally induced myasthenia gravis. ( Apostolski, S; Bartlett, RR; Damjanovic, M; Isakovic, K; Kosec, D; Vidic-Dankovic, B, 1995) |
| "Experimental tubulointerstitial nephritis (TIN), induced in Brown Norway rats, is an autoimmune disorder in which afflicted animals display high levels of serum autoantibodies directed against antigens present on the tubular basement membrane (TBM)." | 5.28 | Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. ( Bartlett, RR; Langer, KH; Schleyerbach, R; Sitter, T; Thoenes, GH, 1989) |
| " Leflunomide (CAS 75706-12-6), a drug approved for the treatment of treat rheumatoid arthritis (RA), was identified as an inhibitor of DHODH." | 4.87 | Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases. ( Leban, J; Vitt, D, 2011) |
| " The earlier use of methotrexate and the introduction of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis have changed the natural characteristics of the disease." | 4.87 | [Systemic autoimmune disorders and pregnancy]. ( Kiss, CG; Kiss, E; Poór, G, 2011) |
| " This article reviews the place of leflunomide in clinical practice and outlines its potential applications beyond its licenced indication, rheumatoid arthritis." | 4.82 | The broadening use of leflunomide in clinical practice. ( Kiely, PD, 2004) |
| "Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis." | 4.81 | Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. ( Harisdangkul, V; Sanders, S, 2002) |
| "Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA)." | 4.80 | Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. ( Herrmann, ML; Kirschbaum, BJ; Schleyerbach, R, 2000) |
| "Leflunomide is a new immunomodulatory drug that is effective in experimental models of autoimmune diseases and in allo or xenotransplantation." | 4.79 | Leflunomide and malononitrilamides. ( Morris, RE; Silva Júnior, HT, 1997) |
| "To investigate the protective efficacy of leflunomide on the Lewis rats with experimental autoimmune uveitis (EAU)." | 3.81 | [Effects of leflunomide on experimental autoimmune uveitis in Lewis rats]. ( Fang, C; He, Y; Huang, C; Li, J; Lin, Z; Zhan, S; Zhou, D, 2015) |
| "To investigate the efficacy of leflunomide in experimental autoimmune uveitis (EAU) in rats." | 3.79 | Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. ( Fang, CB; He, Y; Huang, C; Li, J; Lin, Z; Zhan, SX; Zhou, DX, 2013) |
| "Leflunomide (LEF) is effective not only in different animal models of autoimmune diseases and the therapy of patients with rheumatoid arthritisbut also in graft rejection." | 3.78 | The effects of leflunomide on CD4(+)CD25 (+)Foxp3 (+) T regulatory cells in mice receiving allogeneic bone marrow transplantation. ( Duan, K; Jin, D; Peng, J; Zhang, L; Zhao, Y, 2012) |
| "To evaluate efficacy and adverse effects of leflunomide for the treatment of naturally occurring immune-mediated polyarthritis (IMPA) in dogs." | 3.76 | Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). ( Baker, TA; Colopy, SA; Muir, P, 2010) |
| "Leflunomide (LEF) is a novel immunomodulator which has been reported to be efficacious in experimental models of systemic autoimmune diseases and in treating rheumatoid arthritis in man." | 3.69 | Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. ( Lang, LS; Robertson, SM, 1994) |
| "Leflunomide has been successfully used for treating rheumatoid arthritis and psoriatic arthritis for many years." | 2.52 | Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. ( Brooks, JB; Fragoso, YD, 2015) |
| "Leflunomide has been shown to be very effective in preventing and curing several autoimmune animal diseases." | 2.38 | Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. ( Bartlett, RR; Bremer, E; Dimitrijevic, M; Germann, T; Küchle, CC; Mattar, T; Rüde, E; Schorlemmer, HU; Thoenes, GH; Zielinski, T, 1991) |
| "Leflunomide is an isoxazol derivative with immunosuppressive capacities in various experimental allo- and xenotransplantation models." | 1.31 | Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine. ( Fehr, T; Ochsenbein, AF; Pinschewer, DD; Zinkernagel, RM, 2001) |
| "Brequinar sodium (BQR) was originally developed as an antitumor drug and subsequently as an immunosuppressant for controlling transplant rejection." | 1.30 | Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action. ( Blinder, L; Chong, AS; Gong, H; Shen, J; Williams, JW; Xu, X, 1997) |
| "Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function." | 1.29 | Leflunomide prevents the development of experimentally induced myasthenia gravis. ( Apostolski, S; Bartlett, RR; Damjanovic, M; Isakovic, K; Kosec, D; Vidic-Dankovic, B, 1995) |
| "Experimental tubulointerstitial nephritis (TIN), induced in Brown Norway rats, is an autoimmune disorder in which afflicted animals display high levels of serum autoantibodies directed against antigens present on the tubular basement membrane (TBM)." | 1.28 | Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. ( Bartlett, RR; Langer, KH; Schleyerbach, R; Sitter, T; Thoenes, GH, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 12 (36.36) | 18.2507 |
| 2000's | 7 (21.21) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, K | 1 |
| Chen, Y | 1 |
| Liu, S | 1 |
| He, C | 1 |
| Yang, Y | 1 |
| Wu, D | 1 |
| Wang, L | 1 |
| Li, M | 1 |
| Zeng, X | 1 |
| Zhang, F | 1 |
| Hammad, I | 1 |
| Porter, TF | 1 |
| Wang, Y | 1 |
| Li, K | 1 |
| Gao, D | 1 |
| Luo, G | 1 |
| Zhao, Y | 2 |
| Wang, X | 1 |
| Zhang, J | 2 |
| Jin, J | 1 |
| Zhao, Z | 1 |
| Yang, C | 1 |
| Zhu, J | 1 |
| Huang, F | 1 |
| Fang, CB | 1 |
| Zhou, DX | 1 |
| Zhan, SX | 1 |
| He, Y | 2 |
| Lin, Z | 2 |
| Huang, C | 2 |
| Li, J | 2 |
| Fragoso, YD | 1 |
| Brooks, JB | 1 |
| Fang, C | 1 |
| Zhou, D | 1 |
| Zhan, S | 1 |
| Colopy, SA | 1 |
| Baker, TA | 1 |
| Muir, P | 1 |
| Leban, J | 1 |
| Vitt, D | 1 |
| Prasad, R | 1 |
| Singh, UK | 1 |
| Mittal, R | 1 |
| Mishra, OP | 1 |
| Kiss, E | 1 |
| Kiss, CG | 1 |
| Poór, G | 1 |
| Jin, D | 1 |
| Duan, K | 1 |
| Zhang, L | 1 |
| Peng, J | 1 |
| Palazzo, E | 1 |
| Yahia, SA | 1 |
| Frieling, U | 1 |
| Luger, TA | 1 |
| Mayer, DF | 1 |
| Kushwaha, SS | 1 |
| Kiely, PD | 1 |
| Vidic-Dankovic, B | 1 |
| Kosec, D | 1 |
| Damjanovic, M | 1 |
| Apostolski, S | 1 |
| Isakovic, K | 1 |
| Bartlett, RR | 6 |
| Robertson, SM | 1 |
| Lang, LS | 1 |
| Anagnostopulos, H | 1 |
| Zielinski, T | 3 |
| Mattar, T | 2 |
| Schleyerbach, R | 3 |
| Brazelton, TR | 1 |
| Morris, RE | 2 |
| Brendel, S | 1 |
| Schorlemmer, HU | 2 |
| Silva Júnior, HT | 1 |
| Xu, X | 2 |
| Blinder, L | 2 |
| Shen, J | 3 |
| Gong, H | 2 |
| Finnegan, A | 1 |
| Williams, JW | 3 |
| Chong, AS | 3 |
| Guo, Z | 1 |
| Mital, D | 1 |
| Tian, Y | 1 |
| Foster, P | 1 |
| Sankary, H | 1 |
| McChesney, L | 1 |
| Jensik, SC | 1 |
| Dimitrijevic, M | 3 |
| Milenkovic, M | 1 |
| Milosavljevic, P | 1 |
| Colic, M | 1 |
| Stosic-Grujicic, S | 1 |
| Bartlett, R | 1 |
| Herrmann, ML | 1 |
| Kirschbaum, BJ | 1 |
| Pinschewer, DD | 1 |
| Ochsenbein, AF | 1 |
| Fehr, T | 1 |
| Zinkernagel, RM | 1 |
| Sanders, S | 1 |
| Harisdangkul, V | 1 |
| Wozel, G | 1 |
| Pfeiffer, C | 1 |
| Germann, T | 1 |
| Rüde, E | 1 |
| Thoenes, GH | 2 |
| Küchle, CC | 1 |
| Bremer, E | 1 |
| Sitter, T | 1 |
| Langer, KH | 1 |
| Popovic, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial (Preservation of Pancreatic Production of Insulin Through Immunosuppression-POPPII #1)[NCT00100178] | Phase 2 | 126 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome is the area under the stimulated C-peptide curve (AUC) based on data collected at time 0 to 2 hours of a 4-hour mixed meal glucose tolerance test (MMTT) conducted at the primary endpoint visit. The timed measurements are done at: 0, 15, 30 60, 90, and 120 minutes. (NCT00100178)
Timeframe: 2 years
| Intervention | pmol/ml (Geometric Mean) |
|---|---|
| MMF and DZB | 0.28 |
| Placebo Control | 0.27 |
| MMF Alone | 0.25 |
19 reviews available for leflunomide and Autoimmune Disease
| Article | Year |
|---|---|
Leflunomide: Traditional immunosuppressant with concurrent antiviral effects.
Topics: Antiviral Agents; Autoimmune Diseases; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide | 2023 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani | 2020 |
Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Topics: Autoimmune Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; | 2017 |
Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Crotonates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxaz | 2015 |
Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Dihydroorotate | 2011 |
Immunosuppressive therapy in children.
Topics: Antilymphocyte Serum; Autoimmune Diseases; Azathioprine; Child; Cyclophosphamide; Cyclosporine; Gluc | 2011 |
[Systemic autoimmune disorders and pregnancy].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Antiphospholipid Syndrome; Arthrit | 2011 |
Progressive multifocal leukoencephalopathy in autoimmune diseases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rhe | 2012 |
Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases.
Topics: Administration, Oral; Autoimmune Diseases; Female; Fertility; Fetal Death; Humans; Immunosuppressive | 2002 |
Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases.
Topics: Autoimmune Diseases; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2003 |
The broadening use of leflunomide in clinical practice.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Immunosuppressive Agents; | 2004 |
Effects of leflunomide on immune responses and models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Autoimmune Diseases; Cytokines | 1993 |
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.
Topics: Animals; Autoimmune Diseases; Graft Rejection; Humans; Immunosuppressive Agents; Isoxazoles; Lefluno | 1996 |
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Arthritis, Rheumatoid; Autoimm | 1996 |
Leflunomide and malononitrilamides.
Topics: Aniline Compounds; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Cr | 1997 |
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Dihydr | 2000 |
Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials | 2002 |
[Leflunomide--a new drug for pharmacological immunomodulation].
Topics: Animals; Autoimmune Diseases; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Psoriasis; | 2002 |
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.
Topics: Amino Acid Sequence; Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Disease | 1991 |
14 other studies available for leflunomide and Autoimmune Disease
| Article | Year |
|---|---|
Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.
Topics: Animals; Autoimmune Diseases; Chemokines; Disease Models, Animal; Eye; Female; Gene Expression Regul | 2013 |
[Effects of leflunomide on experimental autoimmune uveitis in Lewis rats].
Topics: Animals; Autoimmune Diseases; Cyclosporine; Down-Regulation; Eye Proteins; Immunosuppressive Agents; | 2015 |
Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Autoimmune Diseases; Dog Diseases; Dogs | 2010 |
The effects of leflunomide on CD4(+)CD25 (+)Foxp3 (+) T regulatory cells in mice receiving allogeneic bone marrow transplantation.
Topics: Animals; Antibodies, Monoclonal; Autoimmune Diseases; Bone Marrow Transplantation; CD4-Positive T-Ly | 2012 |
Leflunomide prevents the development of experimentally induced myasthenia gravis.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Female; Flow Cytometry; Immunization; Immunosuppressiv | 1995 |
Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats.
Topics: Administration, Oral; Administration, Topical; Animals; Antibodies; Antigens; Arrestin; Autoimmune D | 1994 |
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Topics: Aniline Compounds; Animals; Autoimmune Diseases; Crotonates; Dihydroorotate Dehydrogenase; Hydroxybu | 1997 |
Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Biphenyl Compounds; Cytidine Triphosphate; Female; Imm | 1997 |
Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice.
Topics: Animals; Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Graft Reje | 1998 |
Effects of leflunomide on experimental autoimmune myocarditis with special reference to the dendritic cells.
Topics: Animals; Autoimmune Diseases; Dendritic Cells; Freund's Adjuvant; Heart; Immunosuppressive Agents; I | 1998 |
Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes.
Topics: Animals; Autoimmune Diseases; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, | 1999 |
Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
Topics: Animals; Antibodies, Viral; Antibody Formation; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Dia | 2001 |
Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Autoimmune Diseases; Basement Memb | 1989 |
Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Isoxazoles; Leflunomide; Lupus Erythematosus | 1986 |